Drug-based strategies to overcome tumour resistance to radiotherapy (R-RT) remain limited by the single-agent toxicity of traditional radiosensitizers (for example, platinums) and a lack of targeted alternatives. In a screen for compounds that restore radiosensitivity in p53 mutant zebrafish while tolerated in non-irradiated wild-type animals, we identified the benzimidazole anthelmintic oxfendazole. Surprisingly, oxfendazole acts via the inhibition of IRAK1, a kinase thus far implicated in interleukin-1 receptor (IL-1R) and Toll-like receptor (TLR) immune responses. IRAK1 drives R-RT in a pathway involving IRAK4 and TRAF6 but not the IL-1R/TLR-IRAK adaptor MyD88. Rather than stimulating nuclear factor-κB, radiation-activated IRAK1 prevented apoptosis mediated by the PIDDosome complex (comprising PIDD, RAIDD and caspase-2). Countering this pathway with IRAK1 inhibitors suppressed R-RT in tumour models derived from cancers in which TP53 mutations predict R-RT. Moreover, IRAK1 inhibitors synergized with inhibitors of PIN1, a prolyl isomerase essential for IRAK1 activation in response to pathogens and, as shown here, in response to ionizing radiation. These data identify an IRAK1 radiation-response pathway as a rational chemoradiation therapy target.
R adiotherapy induces cytotoxic DNA breaks in tumour cells while minimizing damage to healthy tissues, and is given to ~60% of patients with cancer over the course of treatment 1, 2 . Current approaches to overcoming tumour R-RT consist of concurrent systemic chemotherapy with classical anticancer agents such as genotoxins (for example, cisplatin and 5-fluorouracil) and microtubule inhibitors (for example, taxanes). These traditional radiosensitizers primarily act by augmenting DNA damage levels, thus enhancing cell killing within the field of radiation [1] [2] [3] [4] . Radiosensitizers can be effective; for example, cisplatin-based chemoradiation therapy (CRT) improves survival by 10% compared to RT alone in patients with head and neck squamous cell carcinoma (HNSCC) and is the current standard of care in this cancer 5 . However, tumours recur in a large majority of patients, leading to invariably fatal disease. Further improvements of CRT have remained limited by the toxicity of radiosensitizers as single agents 2, 3 . Moreover, these genotoxic drugs were not designed against-and thus do not necessarily target-the genetic defects or signalling pathways that drive tumour R-RT. Devising targeted strategies to supplant these cytotoxic chemotherapies is a current central focus of the Radiation Therapy Oncology Group of the US National Cancer Institute 1 and the Clinical and Translational Radiotherapy Research Working Group of the The National Cancer Research Institute (UK) 2 .
A candidate and potentially pervasive mechanism of tumour R-RT is mutation of the p53 transcription factor, which occurs in ~50% of solid tumours 6 . Cells with mutant p53 fail to initiate apoptotic or senescence gene-expression programmes in response to ionizing radiation (IR)-induced DNA breaks [7] [8] [9] . In HNSCC 10, 11 , colorectal cancer (CRC) 12, 13 , breast cancer 14 , glioblastoma 15 and medulloblastoma 16 , patients with missense TP53 mutations have markedly worse outcomes following RT or CRT compared with patients with wild-type (WT) TP53, with declines in recurrencefree or overall survival ranging from ~33% to 100%. Yet, patients are not stratified by TP53 status and there are currently no drugs reported to improve RT outcomes in TP53 mutant tumours 1, 2 .
Results
In vivo zebrafish radiosensitizer screen identifies oxfendazole. To identify such genotype-directed radiosensitizers while accounting for the problem of systemic toxicity, we developed a wholeanimal model of mutant TP53-driven R-RT for use in unbiased genetic and chemical screens 17, 18 . In this model, zebrafish embryos Articles NATuRe CeLL BIoLogy homozygous for the M214K (MK) mutation in tp53 display fully penetrant R-RT. This is evidenced by a complete lack of cell death induction in response to IR, a phenotype scored in 24-48 h post fertilization (h.p.f.) embryos 17, 18 ( Supplementary Fig. 1a,b ). Moreover, p53 MK/MK mutants exhibit a complete lack of IR-induced dorsal tail curvatures (DTCs), a morphological manifestation of zebrafish radiosensitivity 19 assessable by eye in 96-120 h.p.f. larvae (Fig. 1a ). The mutated M214 residue corresponds to M246 in human p53, which maps to the mutational hotspot region in the DNA-binding domain and is mutated in > 150 human tumours sequenced thus far 6 . In a pilot candidate gene-based screen, we found that inhibitors of checkpoint kinase 1 (CHK1), such as Gö6976, restore WT levels of IR-induced cell death in p53 MK/MK embryos, with minimal toxicity in the absence of IR 18 (Supplementary Fig. 1a,b ). Such potent radiosensitization by means of CHK1 inhibition was also evident in the late DTC assay, whereby Gö6976 restored DTC formation in ~75% of the mutants with no effects in the absence of IR ( Fig. 1a,b ; Supplementary Fig. 1d ). Gö6976 therefore provided a positive control for large-scale radiosensitizer screens exploiting the morphological DTC phenotype as a readout.
In a screen of 1,151 small molecules (including 640 drugs approved by the US Food and Drug Administration (FDA)), we identified one compound, oxfendazole, which radiosensitized p53 MK/MK mutants with both greater potency and lesser toxicity than Gö6976 ( Fig. 1b; Supplementary Fig. 1c-g ; Supplementary  Tables 1 and 2) . Importantly, these effects were observed at concentrations tolerated by non-irradiated WT embryos (Fig. 1c ). Radiosensitization by oxfendazole was retained in mutant p53depleted p53 MK/MK embryos ( Supplementary Fig. 2a -c) and was apoptotic in nature, as evidenced by acridine orange, TUNEL 37 Cs-irradiated p53 MK/MK zebrafish embryos (15 Gy total body irradiation (TBI) at 18 h.p.f.) observed at 120 h.p.f. lack the DTC phenotype of WT embryos (arrowheads indicate a late readout of embryonic radiosensitivity). DTCs are restored with a CHK1 inhibitor (Gö6976, 1 µ M) in an average of 75% of mutants per experiment ( Supplementary  Fig. 1d ). b, Rescreen of the top 136 hits from a primary screen ( Supplementary Fig. 1c -g) scored for potency (percentage of DTC after γ IR) and selectivity ((percentage of DTC after γ IR)/(percentage of DTC without γ IR)), identifying oxfendazole (OXF) as the top hit. Capecitabine (CAPE) and rapamycin (RAPA), two known clinical radiosensitizers, were also recovered in the blind screen, providing internal validation of the DTC assay. . n = 2 independent experiments for the remaining data points, as indicated by the dot plots and as detailed in Supplementary Fig. 5 , with > 21 embryos scored per experiment. **P < 0.005, ***P < 0.0005 (two-tailed Student's t-test, α = 0.05). See Supplementary  Table 4 for statistics source data, including precise P values. Scale bars, 0.5 mm (a,c) and 0.2 mm (d).
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(TdT-mediated dUTP nick end labelling) and active caspase-3 stains of 48 h.p.f. embryos examined 30 h post-IR (hpIR) ( Fig. 1d ). Oxfendazole-mediated radiosensitization was also associated with an increase in DNA damage levels ( Supplementary Fig. 2d ,e), and was dose-and time-dependent, with maximal efficacy when administered 0-4 hpIR ( Supplementary Fig. 2g -i).
Target discovery for oxfendazole identifies IRAK1. Oxfendazole is a benzimidazole anthelmintic approved for the treatment of worm infections in livestock 20, 21 . Because other microtubule inhibitors, such as taxanes, are commonly used as radiosensitizers 4 , we initially considered tubulin inhibition as the mechanism for oxfendazolemediated radiosensitization. Unexpectedly, none of seven tubulinbinding analogues of oxfendazole, including the classical antimitotic nocodazole, could phenocopy the drug (the in vivo structure-activity relationship is shown in Fig. 1e ). Specifically, while the analogues could produce DTCs as efficiently as oxfendazole, none showed any selectivity for IR (with the possible exception of ricobendazole) and induced DTCs in the mutants regardless of radiation ( Fig. 1e ). Thus, tubulin inhibition is unlikely to fully account for, if even involved in, the radiosensitizing properties of oxfendazole. It is notable in this regard that of all the benzimidazoles tested, oxfendazole and ricobendazole have the lowest affinity for tubulin 20 .
To identify the novel target (or targets) of oxfendazole whose inhibition might drive radiosensitization, we used the similarity ensemble approach (SEA) target-prediction algorithm 22 (Fig. 2a ). SEA yielded 12 candidate targets, which we then tested for their ability to phenocopy oxfendazole when inhibited by specific inhibitors in vivo ( Fig. 2b; Supplementary Fig. 2j ). This analysis identified the IL-1 receptor (IL-1R)-associated kinases IRAK1 and IRAK4 23, 24 as targets, and inhibition of these by an IRAK1/4 kinase inhibitor 25 radiosensitized p53 MK/MK embryos with a potency nearing that of oxfendazole (Figs. 2b-d and 3a; Supplementary Fig. 2j ). Kinasebinding and in vitro kinase assays demonstrated that oxfendazole is a selective IRAK1 inhibitor ( Fig. 2h ,i). The observed dissociation constant (K d of 5.8 μ M) and half-maximum inhibitory concentration (IC 50 of 38 μ M) were consistent with concentrations of oxfendazole that radiosensitize zebrafish p53 MK/MK mutants ( Fig. 1e ). Docking of oxfendazole onto IRAK4-derived zebrafish and human IRAK1 models 26 predicted drug binding to the ATP-binding site and an interaction with the hinge region via the benzimidazolyl carbamate moiety, while the phenylsulfoxide moiety resides in a pocket adjacent to the DFG motif ( Fig. 2e-g ).
IRAK1 is known as an effector of the IL-1R and TLRs in innate immune signalling 27 . It acts through the TRAF6 E3 ubiquitin ligase to stimulate nuclear factor-κ B (NF-κ B), p38 MAPK, JNK and ERK prosurvival and inflammatory responses to pathogens 23, 24 . IRAK1 had not been previously implicated in the DNA damage response or cellular response to RT. Yet, inspection of The Cancer Genome Atlas (TCGA) cohort revealed significant overexpression of IRAK1 in HNSCC and breast cancer samples harbouring TP53 mutant genotypes compared to WT, as well as tumours from patients with breast cancer who ultimately received RT as part of their treatment ( Supplementary Fig. 3a ,i,j; P < 0.0001, P < 0.0001 and P < 0.05, respectively, Wilcoxon rank-sum test). We also found that IRAK1 is commonly activated in response to IR in TP53 mutant HNSCC-, breast cancer-and CRC-derived cell lines, correlating with pronounced R-RT phenotypes ( Fig. 5d ,g,h). We therefore further investigated IRAK1 as a target for inhibition in tumour R-RT.
We first sought to confirm the oxfendazole and IRAK1/4 inhibitor data with additional IRAK1 inhibitors and gene targeting in zebrafish p53 MK/MK embryos, as well as TP53 mutant human cancer cells. For IRAK1 inhibition, we selected the tyrosine kinase inhibitor R406, which inhibits IRAK1 with an IC 50 of 9.7 nM compared with 150 nM for IRAK4 28 , and ginsenoside-Rb1, a ginseng extract that inhibits IRAK1 but not IRAK4 or IRAK2 29 . Whether in zebrafish p53 MK/MK mutants, HeLa cells (devoid of p53 protein via human papillomavirus E6) or TP53 mutant or null human cancer cell lines, genetic or pharmacological inhibition of IRAK1 was consistently incompatible with cell survival in the presence of IR but tolerated in the absence of IR (Figs. 2j, 3a-f, 4a and 5e; Supplementary  Fig. 4a-f ). Both the zebrafish and human cell IRAK1 knockdown models were rescued by WT but not kinase dead 30 (KD) human IRAK1 (Figs. 3e-g and 4c). Importantly, overexpression of WT, but not KD, IRAK1 was sufficient to confer R-RT to otherwise radiosensitive Daoy MB cells (Fig. 4b ). Finally, CRISPR (clustered regularly interspaced short palindromic repeats)-Cas9 gene editing confirmed the essential requirement of the kinase for cell survival specifically after IR ( Fig. 4d ).
IRAK1 drives R-RT independently of its IL-1R/TLR adaptor MyD88 and of canonical downstream pathways.
Both the proximal activator and proximal effector of IRAK1 in IL-1R and TLR signalling-IRAK4 and TRAF6, respectively 23, 24, 27 -were also required for cell survival after IR (Fig. 4e ). IRAK4 was necessary for IR-induced activation of IRAK1, as assessed by T209 phosphorylation 31, 32 (Fig. 4f ), while an IRAK1 mutant deficient in TRAF6binding, IRAK1 E3A (E544A/E587A/E706A) 33 , afforded only partial rescue of irak1-depleted p53 MK/MK embryos ( Fig. 3e -g). By contrast, the adaptor protein MyD88-which bridges IRAK1 and IRAK4 to IL-1R and TLRs and is essential for IRAK1 and IRAK4 activation in innate immunity 23, 24, 27, 34 -was dispensable for both IR-induced IRAK1 T209 phosphorylation and overall R-RT in HeLa cells and p53 MK/MK zebrafish ( Fig. 4e -i; Supplementary Fig. 4g ,k,l). In further contrast to canonical IRAK1 immune signalling, the kinase did not engage NF-κ B, p38 MAPK, JNK or ERK signalling in response to IR ( Fig. 4j ; Supplementary Fig. 4h ). Moreover, an IRAK1 mutant deficient in NF-κ B essential modulator (NEMO) binding, IRAK1 K2R (K134R/K180R) 35 , restored R-RT in IRAK1-depleted p53 MK/MK zebrafish as efficiently as WT IRAK1 ( Fig. 3e-g ).
IR-activated IRAK1 acts to suppress PIDDosome-mediated apoptosis.
Instead of acting through its aforementioned canonical signalling pathways, we found that IRAK1 drives survival after IR by preventing PIDDosome (PIDD-RAIDD-caspase-2) signalling, a DNA damage-inducible apoptotic axis that does not require p53 for activation or function after IR [36] [37] [38] . Indeed, depletion or deletion of IRAK1 triggered caspase-2 maturation in irradiated cells in a PIDD-and RAIDD-dependent manner ( Fig. 4k ,l; Supplementary  Fig. 4i ,j). Moreover, IRAK1 inhibitor-mediated radiosensitization was abolished in cells depleted of PIDD, RAIDD or caspase-2 36 (Fig. 4m ,n). As expected from previous studies 36, 39 , PIDDosomemediated radiosensitization was associated with increased levels of DNA damage ( Supplementary Fig. 2f ). Finally, IRAK1 inhibition after IR was sufficient to enable ATM-mediated phosphorylation of the PIDD death domain (PIDDpT788) ( Fig. 4k ; Supplementary  Fig. 4i ), an event necessary and sufficient for RAIDD recruitment and PIDDosome formation 36 . Together, these data point to an evolutionarily conserved role for IRAK1 in protecting cells against IR-induced cell death, acting in a pathway related to, but genetically distinct from, IL-1R/TLR signalling.
IRAK1 inhibitors restore radiosensitivity in multiple cell models of tumour R-RT.
To evaluate the robustness of the IRAK1targeting strategy, we analysed the radiosensitizing properties of IRAK1 inhibitors across both tumour and TP53 mutation spectra. We assembled a panel of relevant cancer cell lines based on the following three criteria: they must originate from a tumour type in which TP53 mutations adversely affect patient survival after RT or CRT; they must contain a non-synonymous mutation in TP53; and they must have been previously demonstrated as radioresistant in clonogenic assays. A search of the Cancer Cell Line Encyclopedia 40
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NATuRe CeLL BIoLogy combined with a literature search identified 12 such lines derived from HNSCC, medulloblastoma, glioblastoma, CRC and breast cancer ( Fig. 5d ). We also included MCF7 cells, which, while WT for TP53, display profound resistance to IR due to deletion of CASP3 41 . With the exception of the Daoy MB line, all selected cell lines were confirmed as radioresistant in response to 2.5, 5 and up to 7.5 Gy Gate-keeper residue, Y255 (Y288 in human). Three residue changes near the proposed docking pose within the binding site is highlighted in cyan in the zebrafish model: M239, Y257 and M258 (V272, F290 and L291 in the human model). h,i, KINOMEScan in vitro kinase capture assay for indicated kinases (h) and in vitro kinase assay versus IRAK1 (i), curved-fit from two and three replicates, respectively. j, The IRAK1 inhibitor R406 (40 μ g ml -1 ) phenocopies oxfendazole ( Fig. 1d ) in an AO assay at 48 h.p.f., with images representative of two independent experiments. See Supplementary Table 4 for statistics source data, including precise P values. Scale bar, 0.2 mm.
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IR (see Fig. 5b-d and Supplementary Fig. 5 for dimethylsulfoxide (DMSO) columns and corresponding cell viability curves). We therefore screened the panel with the IRAK1 inhibitors R406 and ginsenoside-Rb1 applied at their respective maximum tolerated doses (MTDs), as determined in HeLa cells ( Fig. 5a ), as well as a twofold higher dose (2× MTD). For comparison, we tested cisplatin (MTD and 2× MTD, as above), whose combination with RT is a standard of care in HNSCC and is commonly used in CRT of many other cancers 2 . Cisplatin failed to sensitize any of the TP53 mutant lines to IR, with only marginal additive effects observed in YD38 Table 4 for statistics source data, including precise P values, and Supplementary Fig. 8 for unprocessed immunoblots. Scale bars, 0.5 mm (a) and 0.2 mm (b,e).
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NATuRe CeLL BIoLogy and T98G cells ( Fig. 5d ; Supplementary Fig. 5 ). In stark contrast, ginsenoside-Rb1 and R406 radiosensitized up to 10 and 7 of 11 TP53 mutant lines, respectively (Daoy MB excluded) (see Fig. 5d and Supplementary Fig. 5 for corresponding cell viability curves, and Supplementary Fig. 4d -f for select colony assays). MCF7 radioresistance could not be overcome throughout the screen regardless Gin-Rb1 (10) Gin-Rb1 (20) d HeLa (HPV+) Supplementary Fig. 5 . g, Indicated HeLa shRNA lines treated with or without IR (10 Gy) and analysed by western blotting at 24 hpIR. h, Cell lines as in d treated with or without IR (10 Gy) and analysed by western blotting 24 hpIR. A total of 7 of 9 lines (HeLa, CAL27, SAS, T47D, MDA-MB-231, SW480 and DLD-1, see d) reliably radiosensitized by IRAK1 inhibitors engage IRAK1 phosphorylation in response to IR, while both resistant lines (BHY, MCF7) do not. See Supplementary Table 4 for statistics source data, including precise P values, and Supplementary Fig. 8 for unprocessed immunoblots. Supplementary Fig. 6c,d for quantifications. b, Right: RT-PCR of embryonic mRNA extracts detect nonsense mediated decay of pin1 mRNA. c, Clonogenic assay of shTRIPZ and shPIN1 HeLa cells after up to 5 Gy IR. Surviving fractions to the right. Western blot of PIN1 knockdown also shown in the inset. d, Daoy MB cells transfected with mock, WT or catalytically inactive (W34/K63A) PIN1 exposed to 0 or 7.5 Gy IR and assayed by AlamarBlue at 5 dpIR. Western blot of Flag-PIN1 levels also shown. e, shTRIPZ and shPIN1 CAL27 cells reconstituted with Flag-PIN1 constructs exposed to 0 or 7.5 Gy IR and assayed by AlamarBlue at 5 dpIR. Data in c-e are the mean ± s.d. of n = 3 independent experiments performed in triplicate. *P < 0.05, **P < 0.005 (two-tailed Student's t-test). f, MTD and 2× MTD of buparvaquone (Bup.) and EGCG given to indicated cell lines with 0, 2.5 or 5 Gy IR and analysed by AlamarBlue in n = 3 independent experiments in triplicate. Colour coding as in Fig. 5d . Corresponding survival curves including P values shown in Supplementary Fig. 6n . g-j, Kaplan-Meier curves showing LRR (g), distant metastases (DM, h), disease-free survival (DFS, i) and overall survival (OS, j) in patients from the MD Anderson Cancer Center HNSCC cohort split at median PIN1 expression and analysed by two-sided log-rank test. All patients treated with complete surgical resection followed by postoperative RT. Number of patients were as follows: PIN1 high /TP53 WT, n = 14; PIN1 low /TP53 WT, n = 15; PIN1 high /TP53 mutant (mut), n = 22; PIN1 low /TP53 mutant, n = 21. See Supplementary Table 3 for patient characteristics. k,l, HeLa cells treated with buparvaquone (1 μ g ml -1 ) or EGCG (10 μ g ml -1 ) (k) or stably expressing indicated shRNAs (l) treated with 0 or 10 Gy IR and analysed by western blot at indicated hpIR. See Supplementary Table 4 for statistics source data, including precise P values, and Supplementary Fig. 8 for unprocessed immunoblots.
NATuRe CeLL BIoLogy of drug, drug dose or IR dose. In the great majority of cases, radiosensitization by the IRAK1 inhibitors occurred in those lines that engaged IRAK1 T209 phosphorylation in response to IR (Fig. 5g,h) . Radiosensitization was also obtained at drug doses that were tolerated in the absence of IR (see 0 Gy data points in Fig. 5d and Supplementary Fig. 5 ) and in irradiated non-tumorigenic fibroblasts (IMR-90) and mammary epithelial cells (MCF10A) ( Fig. 5f ; Supplementary Fig. 5 ). Taken together with the zebrafish and HeLa 0  1  2  3  4  5  0  1  2  3  4  5  0  1  2  3  4  5  0  1  2  3 ), R406 (0.1 µ g ml -1 ), ginsenoside-Rb1 (5 µ g ml -1 ) and EGCG (5 µ g ml -1 ); see Fig. 5a ) and indicated γ IR doses (Gy) and analysed by clonogenic assay at 14 dpIR (a, with representative images to the right) or AlamarBlue at 5 dpIR (b). Data are presented as the mean ± s.d. of n = 3 independent experiments (a, b, left) and n = 4 independent experiments (b, right) performed in triplicate. c, p53 MK/MK embryos treated with subtherapeutic doses of EGCG (40 µ g ml -1 ) and R406 (20 µ g ml -1 ) and 0 or 15 Gy TBI at 18 h.p.f. analysed for DTCs at 120 h.p.f. Data are presented as the mean ± s.d. of n = 3 independent experiments, with representative images shown to the right. P value is relative to DMSO-treated irradiated embryos (bar 2). CI, combination index (see Supplementary Fig. 7f ). Scale bar, 0.5 mm. d, Surviving fractions of SAS cells treated with subtherapeutic doses of ginsenoside-Rb1 (5 μ g ml -1 ) and/or EGCG (5 μ g ml -1 ) at indicated IR exposures (Gy), analysed 14 dpIR. Representative images shown below. Data are presented as the mean ± s.d. of n = 3 independent experiments performed in triplicate. e-g, SAS (2 × 10 6 cells)-derived tumour xenografts grown in NSG mice with n = 5 animals per indicated group analysed by haemotoxylin and eosin staining (e) and immunofluorescence confocal microscopy with indicated antibodies (f,g) 24 days post-implantation. See Methods for detailed implantation, RT, drug delivery and staining protocols. Scale bars, 100 μ m (e) and 80 μ m (g). Data in f are from the analysis of n = 4 independent samples per group with 3 independent images (as in g) scored per tumour. Anti-vimentin and anti-active caspase-3 mark human and apoptotic cells, respectively. Unless otherwise indicated, data throughout are expressed as the mean ± s.d., *P < 0.05, **P < 0.005, ***P < 0.0005 (two-tailed Student's t-test). See Supplementary Table 4 for statistics source data, including precise P values.
NATuRe CeLL BIoLogy data, these results identified IRAK1 as a target for inhibition in cancers with mutant TP53-driven R-RT.
An additional predicted oxfendazole target, PIN1 isomerase, drives R-RT in zebrafish and tumour-cell models and associates with R-RT in HNSCC.
Following our analysis of SEA-predicted oxfendazole targets, we noted that inhibition of one additional candidate target, the peptidyl-prolyl cis/trans isomerase PIN1 42 , radiosensitized zebrafish p53 MK/MK mutants with a similar potency to that of the IRAK1/4 inhibitor ( Fig. 2a,b) . While in vitro isomerase and thermal shift assays could not immediately confirm PIN1 as an oxfendazole target ( Supplementary Fig. 6a,b) , genetic or pharmacological inhibition of PIN1 did consistently suppress R-RT in zebrafish ( Fig. 6a,b ; Supplementary Fig. 6c-g) , in HeLa cells ( Fig. 6c ; Supplementary Fig. 6i ,j) and in HNSCC lines (see Fig. 6e ,f and Supplementary Fig. 6n for corresponding cell viability curves, and Supplementary Fig. 6j -m for select colony assays). Similar to IRAK1, PIN1 was sufficient to force R-RT when overexpressed in radiosensitive Daoy MB cells, whereas a catalytically inactive (W34A/K63A) variant 43 was less potent (Fig. 6d) . In further support of PIN1 as a driver of tumour R-RT, overexpression of PIN1 was significantly associated with locoregional recurrence (LRR; P = 0.006) and reduced overall survival (P = 0.007), but not distant metastases, in patients with TP53 mutant HNSCC who were treated with postoperative RT at the MD Anderson Cancer Center 11,44 ( Fig. 6g-j ; Supplementary Table 3 ). Inspection of TCGA HNSCC cohortwhose analysis is however limited by a lack of LRR data 45 -revealed significant upregulation of PIN1 in TP53 mutant tumours that were ultimately treated with RT ( Supplementary Fig. 3f-h) .
PIN1 inhibition prevents IR-induced IRAK1 activation and synergizes with IRAK1 inhibitors in vitro and in vivo.
Interestingly, PIN1 plays an essential and direct role in TLR-induced IRAK1 activation 46 . Similarly, we found that genetic or pharmacological inhibition of PIN1 blocked IR-induced IRAK1 phosphorylation on T209 (Fig. 6k,l) . We therefore tested whether IRAK1 and PIN1 inhibitors synergistically suppress R-RT in our various models. We trialled four combinations of IRAK1 + PIN1 inhibitors, involving the IRAK1 inhibitors ginsenoside-Rb1 and R406 (see above), and the PIN1 inhibitors epigallocatechin gallate (EGCG), a competitive inhibitor with micromolar efficacy shown to bind the PIN1 catalytic site 47, 48 , and buparvaquone, a repurposed antiparasitic that binds and inhibits PIN1 with nanomolar efficacy 49 . Each inhibitor was titrated to a dose that did not decrease HeLa survival as a single agent, even after 2.5 or 5 Gy IR. Under these subtherapeutic conditions, all four combination treatments produced marked synergistic declines in survival specifically after IR (see Fig. 7a and Supplementary Fig. 7a ,e and for combination indexes). These findings were recapitulated in the following models: p53 MK/MK fish ( Fig. 7c; Supplementary Figs. 6h and 7f) ; TP53 mutant HNSCC cell lines grown in vitro ( Fig. 7d; Supplementary Fig. 7b-d ,g) or as tumour xenografts in vivo ( Fig. 7e-g ; Supplementary Fig. 7h) ; TP53 -/as well as WT HCT116 cells ( Supplementary Fig. 7i ); and one of the cell lines from our radioresistant panel that best resisted IRAK1 inhibitors as single agents (SW480 cells; Supplementary  Fig. 7b,g) . All four IRAK1 + PIN1 inhibitor combinations were otherwise tolerated in IMR90 human fibroblasts, including after up to 7.5 Gy IR (Fig. 7b, left) . While MCF10A mammary epithelial cells showed some sensitivity (Fig. 7b, right) , such toxicity was not further exacerbated by IR and was marginal compared with the levels of tumour-cell lethality induced by the various drug combinations in the tumorigenic cell lines (for example, compare 5 Gy data points in Fig. 7b to that in Supplementary Fig. 7a,b) . Clinical translation will require extending these studies to additional in vivo tumour models and TP53 alleles, including in immunocompetent mice. Together, our data collectively identify IRAK1 and PIN1 as rational targets in radioresistant cancers, with efficacy stemming from single or low-dose combination treatments.
Discussion
The data presented here show that IRAK1, a core transducer in innate immune signalling conserved from flies to humans 23, 24, 27 , plays an additional conserved role in the cell survival response to IR. This pathway involves the IL-1R/TLR pathway members PIN1, IRAK4 and TRAF6. However, its MyD88-independence, full reliance on IRAK1 kinase activity, partial reliance on TRAF6 and divergent downstream target (the PIDDosome) are supportive of a distinct stress-response pathway that diverged from, or possibly preceded, the pathogen response. The pathway may respond to one or more IR-induced primary or secondary ionization events, including DNA breakage, micronucleation or other occurrences of cytosolic DNA, hydroxyl radicals or other reactive oxygen species. Ruptured lipid bilayers and/or so-called danger-associated molecular patterns (that is, DNA or nuclear proteins released into extracellular space) may also trigger the pathway 50, 51 . A key feature of this pathway from a therapeutic viewpoint is its IR-induced essentiality, whereby pathway inhibition is lethal to zebrafish or cancer cells exposed to IR but is otherwise tolerated in the absence of IR. Even germline losses of Irak1 or Pin1 are viable in mice 52, 53 . Thus, IRAK1 inhibitor treatment (alone or with a PIN1 inhibitor) could lead to improved tumour radiosensitization strategies whereby drug-induced cytotoxicity is restricted to the field of RT with minimal effects in unexposed tissues. Additionally, the radiosensitzing properties of IRAK1 and PIN1 inhibitors in TP53 mutant tumour cells are not allele-specific and are largely retained in TP53 -/and WT backgrounds. This potentially expands the patient population that might benefit from IRAK1 ± PIN1 inhibitor-based CRT. Finally, recent reports implicate deregulated IRAK1 and PIN1 in tumour progression, maintenance and metastasis, via stabilization of mutant p53 itself 54 and other pathways 23, 32, 34, 42 . Our discovery of these enzymes as drivers of cellular R-RT calls for further development of IRAK1 and PIN1 inhibitors for therapeutic use.
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Methods Zebrafish lines and maintenance. Adult zebrafish were maintained on a 14:10 h light:dark cycle at 28 °C in accordance with the regulations and policies of the Mount Sinai Institutional Animal Care and Use Committee. The study is compliant with all relevant ethical regulations regarding zebrafish research. The progeny of p53 MK/MK fish were used in most experiments. WT zebrafish were from the AB line. The TILLING-mediated generation of the p53 MK/MK line, including allele designation, has been previously described 17, 18 .
Zebrafish drug screen. Live embryos were dechorionated in pronase (2.0 mg ml -1 in egg water) for 7 min and rinsed three times in egg water at 17 h.p.f. At least 15 p53 MK/MK embryos were then arrayed into each well of a 24-well plate and treated with drugs from FDA-approved drug library V1 (Enzo Life Sciences) or proprietary kinase inhibitors (Reddy Lab) at a final concentration of 20 µ g ml -1 in egg water. In the primary screen, three wells were set aside for controls: one negative control, p53 MK/MK + DMSO; and two positive controls, p53 MK/MK + Gö6956 (1 µ M) and p53 +/+ + DMSO. Plates containing drug-treated embryos were γ -irradiated at 18 h.p.f. using a 137 Cs-irradiator (X-ray IR can also be used, but developmental stage and dose differ, presumably due to low-energy electrons). At 6 hpIR, embryos were washed three times and scored at 72 h.p.f. and 120 h.p.f. for curved tails and gross morphological changes. If any well lost embryos to necrosis or manipulation such that fewer than 12 embryos were left before 120 h.p.f., that data point was not included in the analysis and the entire condition was repeated. In the secondary screen, the set-up was similar except two 24-well plates were set-up with identical drug treatments identified in the primary screen, with embryos randomly assigned to each plate. Phenotyping was identical to the primary screen. Again, at least 12 embryos were required to survive until 120 h.p.f. for the data point to be counted, and the secondary screen was performed in three independent experiments. Pictures were obtained of tricaine-anaesthetized embryos mounted on 2-3% methylcellulose and imaged with a Nikon SMZ 1500 fluorescence microscope.
Acridine orange labelling. Live embryos were dechorionated in pronase (2.0 mg ml -1 in egg water) for 7 min and rinsed three times in egg water at 17 h.p.f. After being arrayed and incubated with drugs, depending on the experiment, embryos were then γ -irradiated at 18 h.p.f. using a 137 Cs-irradiator. At 6 hpIR, embryos were labelled live with acridine orange at 10 mg ml -1 in egg water for 20 min, washed three times and analysed using ImageJ as previously described 18 .
Whole-mount TUNEL staining and caspase-3 immunohistochemistry.
The TUNEL cell death assay was performed according to the manufacturer's instructions (ApopTag Fluorescein In Situ Apoptosis Detection kit) with zebrafish manipulations as previously described 18 . Embryos stained for caspase-3 or γ H2AX were fixed in 4% paraformaldehyde overnight at 4 °C and subsequently dehydrated in methanol at − 20 °C for at least 2 h. Embryos were then rehydrated three times for 5 min in PBST (1× PBS, 0.1% Tween-20), and permeabilized by treatment with PDT (PBST, 1% DMSO) supplemented with 0.3% Triton-X for 20 min. Embryos were treated with blocking solution (PDT supplemented with 10% heat-inactivated fetal bovine serum (FBS)) for 30 min before the addition of primary antibody (1:500 anti-activated-caspase-3 (StressGen AAs-103), 1:200 anti-γ H2AX ( Millipore, 05-636)). Embryos were incubated in primary antibody overnight at 4 °C, rinsed three times for 20 min in PDT and then re-blocked for 30 min in blocking solution before the addition of AlexaFluorconjugated secondary antibody (1:250). Immunohistochemistry for TUNEL-and caspase-3-labelled embryos were imaged with a Nikon SMZ 1500 fluorescence microscope. Immunohistochemistry for γ H2AX was imaged with a Leica SP5 DM confocal microscope.
SEA analysis.
Chemical compound SMILES formulas were queried with the online SEA search tool (http://sea.bkslab.org/search/), searching against ChEMBL v.16 Binding 10 µ M. Results for the found benzimidazoles were copied into Microsoft Excel, sorted for duplicates and colour graded according to E-values.
TCGA analysis. TCGA datasets for two cancer types (HNSCC and breast cancer) were obtained from the Broad Institute's Firehose pipeline. Gene expression data were quantile normalized via RSEM and log 2 transformed before analyses for IRAK1 and PIN1. TP53 mutation status and radiation therapy treatment are summarized for each cancer type. Wilcoxon rank-sum test was performed to test the association between gene (IRAK1, PIN1) expression and TP53 mutation status and receipt of radiation therapy. We further analysed IRAK1 and PIN1 expression in TP53 mutant and WT groups across patients who received RT versus those who did not. Survival comparisons were made via a log rank test. Each gene was stratified with respect to its median expression across TP53 status to determine any prognostic association. All analyses were done in R software v.3.4.2 including the 'survival' package. Note that, receipt of radiation is a time varying covariate that can confound survival association through the time it was administered. Date of receipt of radiation is needed to perform this analysis, which is not included in the TCGA dataset 55 .
Chemicals and inhibitors. Oxfendazole, fluocinolone, exemestane, cefepime, pranlukast, amiloride, alfacalcidol and albendazole were obtained from VWR. Amoxapine, ricobendazole and mercazole were obtained from Sigma-Aldrich. Salmeterol, indomethacin, canthaxanthin, bifonzole, rapamycin, mebendazole, fenbendazole and flubendazole were obtained from Santa Cruz Biotechnologies. Misoprostol was obtained from Thermo Fisher, while rebastinib and regorafenib were obtained from Selleck Chem. Gö6976 was obtained from Calbiochem, while lapatinib, SB203580 and SB202190 were gifts from J.A.A.-G. Dabrafenib, sorafenib and vemurafenib were gifts from A. Dar. Recombinant human IL-1β was from Peprotech (200-01B). Doxycycline hyclate was purchased from Sigma (D9891-1G). The following inhibitors were used in this study: IRAK1/4 inhibitor (Sigma, I5409); R406 (Selleck Chemicals, S2194); ginsenoside-Rb1 (Abcam, ab142646, and J&K Scientific, 112127); buparvaquone (Santa Cruz Biotechnology, sc-210970); and EGCG (Sigma, E4268 and E4143). The IRAK1/4 inhibitor was originally discovered in a high-throughput small-molecule screen for IRAK inhibitors, with IC 50 values of 300 nM and 200 nM for IRAK1 and IRAK4, respectively. For 27 other kinases tested during discovery, IC 50 values were > 10,000 nM 25 . Ginsenoside-Rb1 was originally isolated from ginseng extract and identified as a saponin among other components extracted from ginseng. It inhibits IRAK1 in an in vitro kinase assay with an IC 50 of ~10 µ M 29 , with other reported activities against PI3K, AKT, ER-β and enhancement of the NRF2-HO-1 pathway, among others. R406 was originally found to be a SYK inhibitor with an inhibition constant (K i ) of 30 nM 56 , although DiscoverX assays (described below) showed it to also inhibit FLT3, as well as IRAK1 and IRAK4. EGCG was identified as a polyphenolic compound found in green tea, with its earliest effects proposed to be a protectant against the carcinogenic effects of teleocidin and okadaic acid 57 . It was later found to directly bind and inhibit PIN1 with a K i of 20 µ mol per litre 48 . Buparvaquone was derived from a series of anti-Theileria parva (a cattle parasite) compounds, with its primary proposed mechanism as inhibiting the parasite cytochrome b. It was recently found to also inhibit Theileria annulate PIN1 in vitro (no reported IC 50 or K d values) 49 .
In vitro kinase-binding assays (KINOMEScan). KINOMEScan assays (DiscoverX) were performed as follows: kinase-tagged T7 phage strains were prepared in an Escherichia coli host derived from the BL21 strain. E. coli were grown to log-phase and infected with T7 phage and incubated with shaking at 32 °C until lysis. The lysates were centrifuged and filtered to remove cell debris. The remaining kinases were produced in HEK-293 cells and subsequently tagged with DNA for quantitative PCR (qPCR) detection. Streptavidin-coated magnetic beads were treated with biotinylated small-molecule ligands for 30 min at room temperature to generate affinity resins for kinase assays. The liganded beads were blocked with excess biotin and washed with blocking buffer (SeaBlock (Pierce), 1% BSA, 0.05% Tween 20, 1 mM dithiothreitol (DTT)) to remove unbound ligand and to reduce nonspecific binding. Binding reactions were assembled by combining kinases, liganded affinity beads and test compounds in 1× binding buffer (20% SeaBlock, 0.17× PBS, 0.05% Tween 20, 6 mM DTT). Test compounds were prepared as 111× stocks in 100% DMSO. K d values were determined using an 11-point threefold compound dilution series with three DMSO control points. All compounds for K d measurements were distributed by acoustic transfer (noncontact dispensing) in 100% DMSO. The compounds were then diluted directly into the assays such that the final concentration of DMSO was 0.9%. All reactions were performed in polypropylene 384-well plates. Each reaction contained a final volume of 0.02 ml. The assay plates were incubated at room temperature with shaking for 1 h and the affinity beads were washed with wash buffer (1× PBS, 0.05% Tween 20). The beads were then re-suspended in elution buffer (1× PBS, 0.05% Tween 20, 2 μ M non-biotinylated affinity ligand) and incubated at room temperature with shaking for 30 min. The kinase concentration in the eluates was measured by qPCR.
In vitro kinase assays. In vitro kinase assays were performed by Reaction Biology Corporation. Briefly, substrate (myelin basic protein (MBP), 20 µ M final) was freshly prepared in reaction buffer (20 mM HEPES, pH 7.5, 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg ml -1 BSA, 0.1 mM Na 3 VO 4 , 2 mM DTT, 1% DMSO). Human IRAK1 kinase (4 nM) was added to the substrate solution, followed by oxfendazole by acoustic technology (Echo550; nanolitre range). Samples were incubated for 20 min at room temperature before addition of 33 P-ATP (10 μ M final concentration, with specific activity of 10 µ Ci µ l -1 ), then incubated for 2 h at room temperature. Radioactivity was detected using the filter-binding method. Kinase activity data are expressed as the percentage remaining kinase activity in test samples compared to vehicle (DMSO) reactions. Oxfendazole was tested in 10-dose IC 50 mode in triplicate with threefold serial dilution starting at 200 μ M, control compound staurosporine was tested in 10-dose IC 50 mode with fourfold serial dilution starting at 20 μ M. IC 50 values and curve fits were obtained using Prism (GraphPad Software).
Molecular docking.
Protein sequences of the IRAK1 and IRAK4 catalytic domains were aligned with T-Coffee's structure-based alignment mode, Expresso 58 . The IRAK4 X-ray structure (2nru) 26 was used as the template for homology modelling of IRAK1. The homology modelling program MODELLER v.9.15 59 was used to generate ten IRAK1 models with an average ZDOPE 60 score of − 0.64 ± 0.06, suggesting that at least 70% of the atoms are within 3.5 Å of the native IRAK1 structure. Molecular docking to the IRAK1 models was performed with Glide, using the Standard Precision mode and a hydrogen-bond constraint at the hinge region. The docking results from the models were combined to generate the consensus docking result 61 . Oxfendazole and analogues are predicted to dock to the ATP-binding site and to interact with the hinge region with the benzimidazolyl carbamate moiety, while the phenylsulfoxide moiety resides in a pocket adjacent to the DFG motif. The method for zebrafish IRAK1 homology modelling was the same as for human IRAK1. Default settings were used for induced-fit docking of oxfendazole. Specifically, the scaling of van der Waals radii for the receptor atom was changed to 0.75 for atoms with a charge larger than ± 0.15 e 62 .
Microinjections into zebrafish embryos. Human IRAK1 WT, KD and K134R/ K180R were subcloned into the pCS2 + plasmid using restriction enzymes EcoRI and XhoI. The IRAK1 E3A-pCS2 + construct was generated using a Q5 Site-Directed Mutagenesis kit (NEB, E0552S) to produce the E3A variant 63 . All plasmids were linearized by Sac2 single enzyme treatment at 37 °C for 4 h. Digests were stopped by adding 1/20 volume 0.5 M EDTA, 1/10 volume of 3 M sodium acetate and 2 volumes ethanol. Samples were mixed and chilled at − 20 °C for 15 min, washed and resuspended in TE buffer. Sense-capped mRNAs were synthesized for injection using a mMESSAGE mMACHINE SP6 kit (Ambion, AM1340) following the manufacturer's instructions. mRNA concentrations were determined using a Nanodrop spectrophotometer and by RNA gel electrophoresis.
The following mRNAs were co-injected with irak1 morpholinos during the 1-2 cell stage: 20 pg WT IRAK1 mRNA, 25-30 pg IRAK1 KD, 25-30 pg K134R/ K180R or 25-30 pg E3A mutant mRNAs. The zp53-ATG morpholino 64 and zp53-specific 64 antibody (Genetex, GTX128135) were provided by J. Chu. Protein extractions from embryos were performed as previously described 3 and analysed by western blotting as described below. Morpholino antisense oligonucleotides were obtained from Gene Tools. Sequences are as follows:Standard control (std):
Morpholinos were resuspended in sterile water to a stock concentration of 2 mM and delivered into one-cell stage zebrafish embryos by microinjection at various final concentrations with 0.1% phenol red (Sigma).
Sequencing primers for confirming knockdown were as follows: rpp0-F: TAGCCGATCCGCAGACACAC rpp0-R: CTGAACATCTCGCCCTTCTC pin1-e1-F: AGAACATCACACGCAGCAAAG pin1-e3-R: GTGCAAATGAGGCGTCTTCAA irak1-e1-F: GGGTTATGGACTCGCTTTCA irak1-e11-R: CATGCGAGGTCTCTTCTTC Myd88F: TCTTGACGGACTGGGAAACTCG Myd88R: GATTTGTAGACGACAGGGATTAGCC.
PCR with reverse transcription (RT-PCR) and protein extraction from zebrafish embryos. Embryonic RNA was isolated from 24-48 h.p.f. embryos (> 15 embryos per sample) using a standard TRIzol method (250 µ l TRIzol (Invitrogen), 50 µ l CHCl 3 , 175 µ l isopropanol). One microgram of purified RNA was used to generate complimentary DNA using an Invitrogen SuperScript First Strand III RT-PCR kit, with oligo-dT primers. Two micrograms of the cDNA product was loaded on a 1% agarose gel. Pooled embryo protein lysates were collected as previously described 18 .
Cell culture and cell lines. HeLa, HCT116, CAL27, SAS, BHY, HN and Detroit562 cell lines were cultured in DMEM medium (Gibco) supplemented with 10% FBS and 1% penicillin-streptomycin. YD38 cells were cultured in RPMI medium, also supplemented with 10% FBS and 1% penicillin-streptomycin. Experiments requiring combined drug treatment and irradiation were performed as follows: cells were seeded in 10-cm plates and grown to 30-50% confluence. One hour before IR, cells were treated with indicated drugs. Collection of lysates for western blotting after IR typically occurred at 24 hpIR, while collection of cells for fixation and TUNEL staining occurred at 48 hpIR. CAL27, Detroit562, Daoy MB and T98G cells were obtained from American Type Culture Collection. SAS cells were purchased from Health Science Research Resources Bank, BHY from Deutsche Sammlung von Mikroorganismen und Zellkulturen, and YD38 from Korean Cell Line Bank. MDA-MB-231, T47D and MCF7 cells were provided by D. Germain. HeLa stable shPIDD, shRAIDD and shCASP2 cells have been previously described 36 . IMR90 and MCF10A cells were provided by J.A.A.-G. See Supplementary Table 3 for more details on cell line-specific culture media and protocols.
siRNA transfection, shRNA transduction, DNA transfection and constructs. Short interfering RNA (siRNA) transfections were performed using X-tremeGENE siRNA transfection reagent (Roche) and, unless otherwise stated, with 20 nM siRNA according to the manufacturer's instructions. Cells were exposed to IR alone or with Gö6976 or oxfendazole at 48 h post-transfection. Lentiviral short hairpin RNA (shRNA) transduction was performed in HeLa cells as previously described 36 with shTRIPZ, shPIN1 and shIRAK1. shPIDD, shRAIDD and shCASP2 HeLa cells and hairpin sequences have been previously described 36 . DNA transfections were performed as previously described 65 . Human IRAK1 WT and KD 30 were gifts from X. Li. IRAK1 human IRAK1 K134R/K180R in pDEST-515 vector 35 was from J. Ashwell. IRAK1 E3A, derived from WT IRAK1 template, was generated using a Q5 Site-Directed Mutagenesis Kit (NEB, E0552S) to produce the E544A/E587A/ E706A mutations 63 . pBybe-PIN1-WT and pBybe-PIN1-W34K63A have been previously described 66 . siRNAs were also provided by Qiagen, and target sequences were as follows: siIRAK1#5: CCGGGCAATTCAGTTTCTACA siIRAK1#6: TCCCATCGCCATGCAGATCTA siIRAK4#6: ATCCTATTAGTCATATATTTA siMYD88#5: AACTGGAACAGACAAACTATC siTRAF6#7: AGGGTACAATACGCCTTACAA siPIN1#5: GACCGCCAGATTCTCCCTTAA siPIN1#6: CAGTATTTATTGTTCCCACAA. shRNA clones were purchased from Qiagen and mature antisense sequences were as follows:
shIRAK1: ATTACTCAAGGACAACCTG (V3THS_305359) shPIN1. 10N ) was used as the transfection agent. After 24 h, medium containing viral particles was collected and concentrated using Lenti-X Concentrator according to the manufacturer's protocol (Clontech, 631231). Briefly, 1 volume of Lenti-X Concentrator was mixed with 3 volumes of 0.45-µ m filtered viral particle-containing media. The solution was then incubated overnight at 4 °C. The samples were centrifuged at 1,500 × g for 45 min at 4 °C, supernatant aspirated and the pellet resuspended in HeLa and CAL27 cell growth media. For infection, 2 × 10 5 HeLa and CAL27 cells were plated into 6-well plates. The next day, 5 µ M polybrene (Millipore, tr-1003-g) and 200 µ l of concentrated viral particles were added per well. The medium was replaced the next day with medium containing 1 µ g ml -1 puromycin for selection. The IRAK1 sgRNA oligonucleotides (5′ > 3′ ) were as follows: sgRNA1:
(1) CACCGACACGGTGTATGCTGTGAAG (2) AAACCTTCACAGCATACACCGTGTC sgRNA2:
(1) CACCGAGGAGTACATCAAGACGGGA (2) AAACTCCCGTCTTGATGTACTCCTC sgRNA3:
(1) CACCGATTTATCCCACAGAAAGACC (2) AAACGGTCTTTCTGTGGGATAAATC sgRNA4:
(1) CACCGGATCAACCGCAACGCCCCGTG (2) AAACCACGGGCGTTGCGGTTGATCC.
AlamarBlue cell survival assay. Cells were seeded into 96-well plates at densities ranging from 400 to 1,500 cells per well (see Supplementary Table 3 for seeding densities). Eight hours after seeding, if experiments were performed on cells in which shRNA was not previously transfected, drugs were added to the medium, incubated for 1 h, then irradiated. If shRNA lines were used, cells were treated with 1 µ g ml -1 doxycycline for 24 h before irradiation. At 3-4 days post IR, cells were incubated with AlamarBlue (ThermoFisher) at a final concentration of 10%. Absorbance was measured at a wavelength of 570 nm with a 600 nm reference wavelength. Relative fluorescence was calculated using cell-free wells as a control reference, and percentage survival was calculated by comparing with DMSOtreated, non-IR controls. Our web collection on statistics for biologists may be useful.
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Sample size
The sample size for the zebrafish drug screen and mechanistic zebrafish experiments was determined with a power analysis based on preliminary experiments. Irradiated p53M214K/M214K embryos treated with DMSO served as the negative control group with a mean penetrance of curved tails of 5% with a standard deviation of 2.8%. Our positive control used irradiated embryos treated with Go6976, which produced curved tails with a mean penetrance of 86% and a standard deviation of 7.6%. This produced a calculated effect size D of 10.6, which was too high for standard power tables. However, in our preliminary experiments, we observed that our negative control embryos never exceeded 20% penetrance, and positive control group never fell below 75% penetrance, so these were used as the difference in mean, with a maximum standard deviation from those preliminary experiments of 28%, establishing a D of 1.6. For two-tailed t-tests with a significance level of 5% and a power of 90%, the number per group required a sample size of n=lO. To account for attrition of embryos due to washing, pronase, or developmental loss as well as to account for pipetting discrepancies, our protocol established that at least 12 embryos be used for condition.
Data exclusions Exclusion criteria for each zebrafish experiment were as follows: any embryos that were damaged or destroyed during manipulation by washing, pronase treatment, or live imaging were excluded from analysis. Our overall attrition rate due to these manipulations was less than 3% of all embryos used. If any experimental condition (i.e. individual well of zebrafish) yielded exclusion of embryos due to attrition such that the well contained <8 embryos for analysis, the entire condition was excluded due to lack of statistical significance. This condition was then repeated in a new independent experiment. If any 24-or 48-well plate yielded an average attrition rate greater than 3% for all wells in the plate, the experiment was considered compromised and the entire experiment was repeated. Each experiment also contained both negative and positive controls. Negative controls were either nonirradiated AB or p53M214K/M214K for any plate not receiving radiation. For irradiated plates, negative controls were p53M214K/M214K treated with DMSO, and positive controls were p53M214K/M214K embryos treated with Go6976 or oxfendazole in later experiments. Plates were excluded if negative controls yielded phenotypes of >25% AO positivity at 48 hpf or curved tails at 120 hpf OR if positive controls yielded phenotypes of <75% AO positivity or curved tails. For AlamarBlue cell viability experiments, each plate of selected radioresistant cells treated with drugs and subjected to IR contained negative control wells of each cell line treated with DMSO. If IR alone caused a decreased in cell survival relative to non-irradiated controls, with the exception of IR-dose finding experiments or Daoy (described in "Replication" below), the experiment was considered invalid and was repeated.
Replication
All attempts at replication were successful. The primary screen of 640 FDA-approved drugs in zebrafish was not replicated due to its nature as an initial screen. However, if any condition met exclusion criteria, the individual condition was repeated. The secondary screen and all other zebrafish experiments were successfully replicated. The medulloblastoma cell line Daoy were selected based on literature suggesting it was radioresistant, which we could not replicate in AlamarBlue cell viabilities studies. Our data for Daoy were included regardless.
Randomization For all zebrafish experiments, each independent experiment utilized embryos l collected on different days from randomly selected mating pairs according to parental genotype (e .g. AB wild-type or p53M214K/M214K). Fertilized embryos were then pooled before randomly allocating into experimental conditions (e.g. IR vs no-lR and drug treatments) .
Blinding
The zebrafish drug screen described in Fig. 1b and Supplemental Figs. 2-3 was blinded during data acquisition. The identity of the 640 FDAapproved drugs were blinded to experimenters during both primary and secondary screens. After the top hits were selected based on potency and selectivity, the drugs were unblinded for further study and target discovery.
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